Office of Biotechnology Products, Silver Spring, Maryland, USA.
NGM Biopharmaceuticals Inc., South San Francisco, California, USA.
Biotechnol Bioeng. 2022 Mar;119(3):743-761. doi: 10.1002/bit.28017. Epub 2022 Jan 11.
For drug products manufactured in mammalian cells, safety assurance practices are needed during production to assure that the final medicinal product is safe from the potential risk of viral contamination. Virus filters provide viral retention for a range of viruses through robust, largely size-based retention mechanism. Therefore, a virus filtration step is commonly utilized in a well-designed recombinant therapeutic protein purification process and is a key component in an overall strategy to minimize the risks of adventitious and endogenous viral particles during the manufacturing of biotechnology products. This study summarizes the history of virus filtration, currently available virus filters and prefilters, and virus filtration integrity test methods and study models. There is also discussion of current understanding and gaps with an eye toward future trends and emerging filtration technologies.
对于采用哺乳动物细胞生产的药物产品,在生产过程中需要采取安全保证措施,以确保最终药物产品不存在潜在的病毒污染风险。病毒过滤器通过强大的、主要基于大小的截留机制,为多种病毒提供病毒截留。因此,病毒过滤步骤通常用于经过精心设计的重组治疗性蛋白纯化过程中,是降低生物技术产品生产过程中外来和内源性病毒颗粒风险的整体策略的关键组成部分。本研究总结了病毒过滤的历史、目前可用的病毒过滤器和预滤器,以及病毒过滤完整性测试方法和研究模型。还讨论了目前的认识和差距,着眼于未来的趋势和新兴过滤技术。